Form 4: TENAX CMO Stuart Rich Acquires 250,000 Stock Options

TENAX THERAPEUTICS, INC. Chief Medical Officer Stuart Rich reported the acquisition of 250,000 new stock options with an exercise price of $13.30, alongside other option grants and existing holdings.

Summary

• Stuart Rich, Chief Medical Officer and Director of TENAX THERAPEUTICS, INC., reported changes in his beneficial ownership of company securities.
• This includes the acquisition of 250,000 stock options with an exercise price of $13.30, vesting over four years starting January 9, 2027, and expiring on January 9, 2036.
• Other derivative holdings include 157 stock options with an exercise price of $2,848, vesting tied to Phase 3 clinical trial milestones and expiring on January 15, 2031.
• An additional 63 stock options with an exercise price of $992 vest in four equal annual installments from June 9, 2023, expiring on June 9, 2032.
• Another 119 stock options with an exercise price of $3.549 vest in four equal annual installments from May 17, 2025, expiring on May 17, 2034.
• Rich also holds 500,000 stock options with an exercise price of $5.94, exercisable from December 10, 2025, and expiring on December 10, 2034.
• A further 625,000 stock options with an exercise price of $5.89 vest over four years starting May 16, 2026, and expire on May 16, 2035.
• Direct beneficial ownership of non-derivative securities includes 5,266 shares of Common Stock.
• Indirect beneficial ownership includes 1,194 shares of Common Stock via the Stuart Rich 2022 Irrevocable Trust, 1,194 shares via the Andrea Rich 2021 Irrevocable Trust, and 5,000 shares via the Stuart Rich Revocable Trust DTD 11/18/1996.

Sentiment

Score: 6

Explanation: The filing reports routine insider option grants, which generally signal management's continued alignment with company performance and future prospects. No significant positive or negative financial news is disclosed.

Positives

• The grant of 250,000 new stock options to the Chief Medical Officer aligns management incentives with long-term shareholder value creation.
• Vesting schedules tied to clinical trial milestones for some options indicate a commitment to advancing the company's product pipeline and achieving key development stages.

Risks

• Vesting of certain stock options is contingent upon continued employment, introducing retention risk for the company.
• Some options' vesting is tied to specific clinical trial milestones (e.g., Phase 3 start, database lock, IND opening, FDA approval), which are subject to inherent risks of drug development and regulatory processes.
• The value of stock options is subject to market price fluctuations, and they may expire worthless if the stock price does not exceed the exercise price.

Future Outlook

The vesting conditions for certain stock options are tied to future company milestones, including the start of a Phase 3 clinical trial, database lock for the trial, opening of an Investigational New Drug Application (IND) with the FDA, and subsequent FDA approval. This indicates a forward-looking strategy focused on drug development and regulatory achievements.

Industry Context

The grant of stock options with vesting tied to clinical trial phases and FDA approvals is a common compensation structure in the biotechnology and pharmaceutical industries, aligning executive incentives with the successful progression of drug candidates through development and regulatory pathways.

Related Party Transactions

• Indirect beneficial ownership of 1,194 common shares through the Stuart Rich 2022 Irrevocable Trust, where the reporting person is a special asset advisor.
• Indirect beneficial ownership of 1,194 common shares through the Andrea Rich 2021 Irrevocable Trust, where the reporting person is co-trustee.
• Indirect beneficial ownership of 5,000 common shares through the Stuart Rich Revocable Trust DTD 11/18/1996, where the reporting person is trustee.

Stakeholder Impact

• Shareholders may view the grant of new stock options to a key executive as a positive sign of management's long-term commitment and alignment with shareholder interests.
• Employees, particularly those involved in clinical development, may see the milestone-based vesting as an indicator of the company's strategic priorities and potential for future success.

Next Steps

• Continued employment of the Chief Medical Officer to meet vesting conditions for stock options.
• Achievement of clinical trial milestones, including the start of a Phase 3 clinical trial, database lock, IND application, and FDA approval, which will trigger vesting for specific option grants.
• Potential exercise of vested stock options by the reporting person in the future.

Key Dates

Keywords

TENAX THERAPEUTICS, TENX, Stuart Rich, Form 4, insider transaction, stock options, beneficial ownership, Chief Medical Officer, corporate governance, equity compensation